XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

Commitments and Contingencies (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended
	Jul. 14, 2023	Jun. 30, 2023	Mar. 31, 2024
Non-cancelable commitments for product manufacturing and supply costs			$ 6.5
Pharmosa License Agreement
Upfront license fee to be paid		$ 10.0
Maximum potential development milestone payments		30.0
Maximum potential sales milestones		185.0
Milestone payments Pharmosa is to receive per terms of the license agreement		$ 10.0
Chasm Technologies
Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties			1.5
Net sales earned relating to payment of future contingent royalties			0.2
Agreement With LGM Pharma, LLC
Purchase Commitment, Remaining Minimum Amount Committed			$ 2.7
Expiration term of agreement			5 years
Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC
Initial term	5 years
Termination term for FDA rejection	60 days
Termination term for FDA delay	120 days
Percentage of reimburse	50.00%
Aggregate exceed	$ 2.5
Term of submission	24 months
Initial term	12 months

X

- Definition

Amount of accrued upfront license fee.

+ References

No definition available.

+ Details

Name:	lqda_AccruedUpfrontLicenseFee
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	lqda_AgreementExpirationTerm
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Initial term of commercial manufacturing services and supply agreement.

+ References

No definition available.

+ Details

Name:	lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period.

+ References

No definition available.

+ Details

Name:	lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Term term upon written notice in the event of application for regulatory approval is rejected by the FDA.

+ References

No definition available.

+ Details

Name:	lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Initial term of submission of quarterly forecast of expected production considered as binding firm order.

+ References

No definition available.

+ Details

Name:	lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The maximum net sales amount that is used as the basis in determining the payment of future contingent royalties.

+ References

No definition available.

+ Details

Name:	lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The maximum potential development milestone payments per the agreement.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialDevelopmentMilestonePayments
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The maximum potential sales milestones to be paid.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialSalesMilestones
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of milestone payments payable.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentsPayable
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of net sales earned by the entity relating to payment of future contingent royalties.

+ References

No definition available.

+ Details

Name:	lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of non-cancelable future commitments for product manufacturing and supply costs.

+ References

No definition available.

+ Details

Name:	lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Percentage of reimbursement of documented out of pocket expenditures for any capital equipment.

+ References

No definition available.

+ Details

Name:	lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures
Namespace Prefix:	lqda_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company.

+ References

No definition available.

+ Details

Name:	lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Term of submission of quarterly forecast of expected production.

+ References

No definition available.

+ Details

Name:	lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: